Analysts expect that China Biologic Products Holdings Inc (NASDAQ:CBPO) will report earnings of $1.03 per share for the current fiscal quarter, Zacks Investment Research reports. Zero analysts have provided estimates for China Biologic Products’ earnings. China Biologic Products posted earnings of $1.17 per share in the same quarter last year, which would suggest a negative year-over-year growth rate of 12%. The company is expected to issue its next earnings report on Friday, August 2nd.
On average, analysts expect that China Biologic Products will report full-year earnings of $4.01 per share for the current year, with EPS estimates ranging from $3.93 to $4.09. For the next fiscal year, analysts anticipate that the business will post earnings of $4.24 per share, with EPS estimates ranging from $3.95 to $4.52. Zacks Investment Research’s EPS averages are an average based on a survey of sell-side research firms that cover China Biologic Products.
China Biologic Products (NASDAQ:CBPO) last released its quarterly earnings results on Friday, May 10th. The biopharmaceutical company reported $1.11 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $0.99 by $0.12. The firm had revenue of $129.78 million during the quarter, compared to the consensus estimate of $119.50 million. China Biologic Products had a net margin of 27.71% and a return on equity of 8.81%. During the same quarter last year, the firm earned $1.21 earnings per share.
Hedge funds and other institutional investors have recently made changes to their positions in the stock. Maso Capital Partners Ltd raised its stake in China Biologic Products by 3.3% during the 1st quarter. Maso Capital Partners Ltd now owns 164,500 shares of the biopharmaceutical company’s stock worth $15,011,000 after acquiring an additional 5,300 shares during the period. Greenwoods Asset Management Ltd raised its stake in China Biologic Products by 281.8% during the 1st quarter. Greenwoods Asset Management Ltd now owns 479,580 shares of the biopharmaceutical company’s stock worth $43,762,000 after acquiring an additional 353,980 shares during the period. FIL Ltd raised its stake in China Biologic Products by 1.8% during the 1st quarter. FIL Ltd now owns 519,071 shares of the biopharmaceutical company’s stock worth $47,365,000 after acquiring an additional 8,929 shares during the period. Dalton Investments LLC raised its stake in China Biologic Products by 51.1% during the 1st quarter. Dalton Investments LLC now owns 113,851 shares of the biopharmaceutical company’s stock worth $10,389,000 after acquiring an additional 38,500 shares during the period. Finally, Alpine Global Management LLC bought a new stake in China Biologic Products during the 1st quarter worth approximately $480,000. 35.28% of the stock is owned by institutional investors and hedge funds.
CBPO stock opened at $95.30 on Friday. The company’s fifty day simple moving average is $92.06. The company has a market capitalization of $3.74 billion, a P/E ratio of 23.71, a P/E/G ratio of 4.91 and a beta of 1.27. China Biologic Products has a 52-week low of $60.08 and a 52-week high of $107.44.
About China Biologic Products
China Biologic Products Holdings, Inc engages in the research, development, manufacture, and sale of human plasma-based biopharmaceutical products to hospitals and inoculation centers in the People's Republic of China. It offers human albumin for treating shock caused by blood loss trauma or burn; raised intracranial pressure caused by hydrocephalus or trauma; oedema or ascites caused by hepatocirrhosis and nephropathy; and neonatal hyperbilirubinemia, as well as for the prevention and treatment of low-density-lipoproteinemia.
See Also: How Does the Quiet Period Work?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for China Biologic Products Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for China Biologic Products and related companies with MarketBeat.com's FREE daily email newsletter.